Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities
Open Access
- 22 October 2020
- journal article
- research article
- Published by Springer Nature in Statistics in Biosciences
- Vol. 12 (3) , 468-494
Abstract
The evolving HIV prevention landscape poses challenges to the statistical design of future trials of candidate HIV vaccines. Study designs must address the anticipated reduction in HIV incidence due to adding new prevention modalities to the standard prevention package provided to trial participants, and must also accommodate individual choices of participants with regard to the use of these modalities. We explore four potential trial designs that address these challenges, with a focus on accommodating the newest addition to the prevention package-antiretroviral-based oral pre-exposure prophylaxis (PrEP). The designs differ with respect to how individuals who take up oral PrEP at screening are handled. An All-Comers Design enrolls and randomizes all eligible individuals, a Decliners Design enrolls and randomizes only those who decline PrEP at screening, and Single and Multi-Stage Run-In Designs enroll all but randomize only those who decline PrEP or show inadequate adherence to PrEP after one or multiple run-in periods. We compare these designs with respect to required sample sizes, study duration, and resource requirements, using a simulation model that incorporates data on HIV risk and PrEP uptake and adherence among men who have sex with men (MSM) in the Americas. We advocate considering Run-In Designs for some future contexts, and identify their advantages and tradeoffs relative to the other designs. The design concepts apply beyond HIV vaccines to other prevention modalities being developed with the aim to achieve further reductions in HIV incidence.Keywords
Funding Information
- National Cancer Institute (P30 CA015704, R01 CA152089)
- National Institute of Allergy and Infectious Diseases (R56 AI143418)
This publication has 36 references indexed in Scilit:
- Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug ExposureAIDS Research and Human Retroviruses, 2013
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- A "SMART" Design for Building Individualized Treatment SequencesAnnual Review of Clinical Psychology, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Efficient design and inference for multistage randomized trials of individualized treatment policiesBiostatistics, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Customizing treatment to the patient: Adaptive treatment strategiesDrug and Alcohol Dependence, 2007
- Developing adaptive treatment strategies in substance abuse researchDrug and Alcohol Dependence, 2007
- Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid usersDrug and Alcohol Dependence, 2007
- An experimental design for the development of adaptive treatment strategiesStatistics in Medicine, 2004